Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons

Journal of Neurocytology

Volumn 32, Issue 4, 2003, Pages 329-343

  Sharma, Sushil K ^a   Carlson, Edward C ^a   Ebadi, Manuchair ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; CELL NUCLEUS DNA; CYTOCHROME C; DNA FRAGMENT; GLUTATHIONE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUROPROTECTIVE AGENT; PHOSPHATIDYLSERINE; REACTIVE OXYGEN METABOLITE; SELEGILINE; SUPEROXIDE DISMUTASE;

APOPTOSIS; ARTICLE; CELL SHAPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME RELEASE; GENE ACTIVATION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NERVE CELL; NERVE CELL MEMBRANE; NERVE CELL NECROSIS; NEUROPROTECTION; ONCOGENE C FOS; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

1-METHYL-4-PHENYLPYRIDINIUM; APOPTOSIS; CELL LINE, TUMOR; CELL MEMBRANE; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICALS; GENES, IMMEDIATE-EARLY; HUMANS; INTRACELLULAR MEMBRANES; MICROSCOPY, ELECTRON; MITOCHONDRIA; NERVE DEGENERATION; NEURITES; NEUROBLASTOMA; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PHOSPHATIDYLSERINES; SELEGILINE;

EID: 1042279466     PISSN: 03004864     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEUR.0000011327.23739.1b     Document Type: Article

References (68)

1. BAUR, P. S. & STACEY, T. R. (1977) The use of PIPES buffer in the fixation of mammalian and marine tissues for electron microscopy. Journal of Microscopy 109, 315-327.
2. BOHR, V. A., STEVNSNER, T. & DE SOUZA-PINTO, N. C. (2002) Mitochondrial DNA repair of oxidative damage in mammalian cells. Gene 286, 127-134.
3. BOULTON, A. A., YU, P. H., DAVIS, B. A., PATERSON, I. A., LI, X. M., JUORIO, A. V., DURDEN, D. A. & DYCK, L. E. (1998) Aliphatic N-methylpropargylamines: Monoamine oxidase-B inhibitors and antiapoptotic drugs. Advances In Pharmacology 42, 308-311.
4. BUYS, Y. M., TROPE, G. E. & TATTON, W. G. (1995) (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Current Eye Research 14, 119-126.
5. CARLILE, G. W., CHALMERS-REDMAN, R. M., TATTON, N. A., PONG, A., BORDEN, K. E. & TATTON, W. G. (2001) Reduced apoptosis after nerve growth factor and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Molecular Pharmacology 57, 2-12.
6. CARLSON, E. C. & HINDS, D. (1981) Native banded collagen fibrils in the glomerular mesengial matrix of normal human and laboratory animals. Journal of Ultrastructural Research 77, 241-247.
7. + opens the mitochondrial permeability transition pore and releases cytochrome C in isolated mitochondria via an oxidative mechanism. Biochimica Biophysica Acta 1453, 49-62.
8. CASSARINO, D. S., HALVORSEN, E. M., SWERDLOW, R. H., ABRAMOVA, N. N., PARKER, W. I. JR., STURGILL, T. W. & BENNETT, J. P. JR. (2000) Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappa-B in cellular models of Parkinson's disease. Journal of Neurochemistry 74, 1384-1392.
9. EBADI, M. (1998) Therapeutic potential of Selegiline in Parkinson's disease and other neurological disorder. In Recent Advances in Neurodegenerative Disorders (edited by MARWAH, J. & TEITELBAUM, H.) pp. 256-350. Prominent Press.
10. EBADI, M. & HIRAMATSU, M. (2000) Glutathione and metallothionein in oxidative stress of Parkinson's disease. In Free Radicals in Brain Pathophysiology (edited by POLI, G., CADENAS, E. & PACKER, L.) pp. 427-465. Marcel Dekker, Inc.
11. EBADI, M. & SHARMA, S. K. (2003) Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxidants and Redox Signaling 5, 319-335.
12. EBADI, M., GOVITRAPONG, P., SHARMA, S., MURALIKRISHNAN, D., SHAVALI, S., PELLET, L., SCHAFER, R., ALBANO, C. & EKEN, J. (2001) Ubiquinone (coenzyme Q10) and mitochondria in oxidative stress of Parkinson's disease. Biosignals & Receptors 10, 224-253.
13. EBADI, M., SHARMA, S., SHAVALI, S. & EL REFAEY, H. (2002) Neuroprotective actions of selegiline. Journal of Neuroscience Research 67, 285-289.
14. ELKON, H., DON, J., MELAMED, E., ZIV, I., SHIRVAN, A. & OFFEN, D. (2002) Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. Journal of Molecular Neuroscience 18, 229-238.
15. FERNANDEZ-GONZALEZ, A., PEREZ-OTANO, I. & MORGAN, J. I. (2000) MPTP selectively induces haem oxygenase-1 expression in striatal astrocytes. European Journal of Neuroscience 12, 1573-1583.
16. GIASSON, B. I., DUDA, J. E., MURRAY, I. V., CHEN, Q., SOUZA, J. M., HURTIG, H. I., ISCHIROPOULOS, H., TROJANOWSKI, J. Q. & LEE, V. M. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 595-597.
17. GOTZ, M. E., DIRR, A., GSELL, W., BURGER, R., JANETZKY, B., FREYBERGER, A., REICHMANN, H., RAUSCH, W. D. & RIEDERER, P. (1994) Influence of N-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine, lipoic acid and L-deprenyl on the interplay between cellular redox systems. Journal of Neural. Transmission 43(Suppl.), 145-162.
18. CROC, L., LEVINE, R. A., FOSTER, J. A., NORMILE, H. J., WEISSMANN, D. & BEZIN, L. (2000) Evidence of deprenyl-insensitive apoptosis of nigral dopamine neurons during development. Brain Research Developmental Brain Research 120, 95-98.
19. GUO, M., CHEN, S., LIU, Z. & CHEN, H. (2001) Eldepryl prevents 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine-induced nigral neuronal apoptosis in mice. Chinese Medical Journal 114, 240-243.
20. HALLIWELL, B. (2001) Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs & Aging 18, 685-716.
21. +)-and nerve growth factor-induced changes in pro- and anti-apoptotic signaling pathways in SH-SY5Y neuroblastoma cells. Brain Research 952, 98-110.
22. HASHIMOTO, M., TAKEDA, A., HSU, L. J., TAKENOUCHI, T. & MASLIAH, E. (1999) Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. Journal of Biological Chemistry 274, 28849-28852.
23. ISCHIROPOULOS, H. & BECKMAN, J. S. (2003) Oxidative stress and nitration in neurodegeneration: Cause, effect, or association. Journal of Clinical Investigation 111, 163-169.
24. JENNER, P. & OLANOW, C. W. (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47, S161-S170.
25. KAKIMURA, J., KITAMURA, Y., TAKEDA, K., KOHNO, Y., NOMURA, Y. & TANIGUCHI, T. (2001) Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. European Journal of Pharmacology 417, 59-67.
26. KOLLER, W. C. (1997) Neuroprotective therapy for Parkinson's disease. Experimental Neurology 144, 24-28.
27. KRAGTEN, E., LALANDE, I., ZIMMERMANN, K., ROGGO, S., SCHINDLER, P., MULLER, D., VAN OOSTRUM, J., WALDMEIER, P. & FURST, P. (1998) Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. Journal of Biological Chemistry 273, 5821-5828.
28. LEE, W., JANKOVIC, J., XIE, W., KONG, R. & APPEL, S. H. (1997) (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neuroscience Letters 224, 197-200.
29. LEE, C., KO, H., SONG, J., & HAN, E. (2002) Effect of R(-)-deprenyl and harmaline on dopamine and peroxynitrite-induced membrane permeability transition in brain mitochondria. Neurochemical Research 27, 215-224.
30. LESUISSE, C. & MARTIN, L. J. (2002) Long-term culture of mouse cortical neurons as a model for neuronal development, aging, and death. Journal of Neurobiology 51, 9-23.
31. MAGYAR, K., SZENDE, B., LENGYEL, J., TARCZALI, J. & SZATMARY, I. (1998) The neuroprotective and neuronal rescue effects of (-)-deprenyl. Journal of Neural Transmission 52(Suppl), 109-123.
32. MARUYAMA, W., AKAO, Y., YOUDIM, M. & NAOI, M (2000) Neurotoxins induce apoptosis in dopaminergic neurons: Protection by N-propargylamine-1 (R)-and (S)-aminoindan, rasagiline and TV1022. Journal of Neural Transmission 60(Suppl), 171-186.
33. MARUYAMA, W., BOULTON, A., DAVIS, B., DOSTERT, P. & NAOI, M. (2001) Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl (R) Salsolinol, in dopaminergic SH-SY5Y cells: Suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. Journal of Neural Transmission 108, 11-24.
34. MATSUBARA, K., SENDA, T., UEZONO, T., AWAYA, T., OGAWA, S., CHIBA, K., SHIMIZU, K., HAYASE, N. & KIMURA, K. (2001) L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP(+) and beta-carbolinium: A microdialysis study in rats. Neuroscience Letters 302, 65-68.
35. NAOI, M., MARUYAMA, W., TAKAHASHI, T., AKAO, Y. & NAKAGAWA, Y. (2000a) Involvement of endogenous N-methyl(R) salsolinol in Parkinson's disease: Induction of apoptosis and protection by (-) deprenyl. Journal of Neural Transmission 58(Suppl), 111-121.
36. NAOI, M., MARUYAMA, W., YAGI, K. & YOUDIM, M. (2000b) Anti-apoptotic function of L-(-) deprenyl (Selegiline) and related compounds. Neurobiology 8, 69-80.
37. NAOI, M. & MARUYAMA, W. (2001) Future of neuroprotection in Parkinson's disease. Parkinsonism and Related Disorders 8, 139-145.
38. OLANOW, C. W. (1996) Deprenyl in the treatment of Parkinson's disease: Clinical effects and speculations on mechanism of action. Journal of Neural Transmission 48(Suppl), 75-84.
39. PATERSON, I. A., BARBER, A. J., GELOWITZ, D. L. & VOLL, C. (1997) (-) Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neuroscience & Biobehavioral Reviews 21, 181-186.
40. PATERSON, I. A., ZHANG, D., WARRINGTON, R. C. & BOULTON, A. A. (1998) R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. Journal of Neurochemistry 70, 515-523.
41. PATERSON, I. A. & TATTON, W. G. (1998) Antiapoptotic actions of monoamine oxidase B inhibitors. Advances in Pharmacology 42, 312-315.
42. PRASAD, K. N., COLE, W. C. & KUMAR, B. (1999) Multiple antioxidants in the prevention and treatment of Parkinson's disease. Journal of American College of Nutrition 18, 413-423.
43. PRZEDBORSKI, S., CHEN, Q., VILA, M., GIASSON, B. I., DJALDATTI, R., VUKOSAVIC, S., SOUZA, J. M., JACKSON-LEWIS, V., LEE, V. M. & ISCHIROPOULOS, H. (2001) Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Journal of Neurochemistry 76, 637-640.
44. SANGCHOT, O., SHARMA, S., CHETSAWANG, B., PORTER, J., GOVITROPONG, P. & EBADI, M. (2002) Deferoxamine attenuates Iron-induced oxidative stress and prevents mitochondrial aggregation and α-synuclein translocation in SK-N-SH cells in culture. Devevelopmental Neuroscience 24, 143-153.
45. SAPORITO, M. S., THOMAS, B. A. & SCOTT, R. W. (2000) MPTP activates c-Jun NH (2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. Journal of Neurochemistry 75, 1200-1208.
46. SEO, J. H., RAH, J. C., CHOI, S. H., SHIN, J. K., MIN, K., KIM, H. S., PARK, C. H., KIM, S., KIM, E. M., LEE, S. H., LEE, S., SUH, S. W. & SUH, Y. H. (2002) Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathways. FASEB Journal 16, 1826-1838.
47. SHARMA, S. K. & EBADI, M. (2003) Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons. Antioxidants and Redox Signaling 5, 251-264.
48. SHERER, T. B., BETARBET, R., STOUT, A. K., LUND, S., BAPTISTA, M., PANOV, A. V., COOKSON, M. R. & GREENAMYRE, J. T. (2002) An in-vitro model of Parkinson's disease: Linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. Journal of Neuroscience 15, 7006-7015.
49. SIENKIEWICZ-JAROSZ, H. & KOSTOWSKI, W. (2000) [Perspectives of therapy of Alzheimer's disease. Psychiatry (Poland) 34, 623-640.
50. SIMON, L., SZILAGYI, G., BORI, Z., ORBAY, P. & NAGY, Z. (2001) (-)-Deprenyl attenuates apoptosis in experimental brain ischaemia. European Journal of Pharmacology 430, 235-241.
51. SLAWEK, J. (2000) Is there an effective neuroprotective treatment of Parkinson's disease? (therapeutic possibilities against the background of etiopathogenetic concepts). Neurology Neurochirology (Poland) 34, 733-742.
52. SOUZA, K. M., GIASSON, B. I., CHEN, Q., LEE, V. M. & ISCHIROPOULOS, H. (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. Journal of Biological Chemistry 275, 18344-18349.
53. SZENDE, B., BOKONYI, G., BOCSI, J., KERI, G., TIMAR, F. & MAGYAR, K. (2001) Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites. Journal of Neural Transmission 108, 25-33.
54. SZENDE, B., MAGYAR, K. & SZEGEDI, Z. (2000) Apoptotic and antiapoptotic effect of (-)deprenyl and (-)-desmethyl-deprenyl on human cell lines. Neurobiology 8, 249-255.
55. TAKAHASHI, T., YAMASHITA, H., NAKAMURA, T., NAGANO, Y. & NAKAMURA, S. (2002) Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Research 938, 73-80.
56. TATTON, W. G., JU, W. Y., HOLLAND, D. P., TAI, C. & KWAN, M. (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. Journal of Neurochemistry 63, 1572-1575.
57. TATTON, W. G., WADIA, J. S., JU, W. Y., CHALMERS-REDMAN, R. M. & TATTON, N. A. (1996) (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. Journal of Neural Transmission 48(Suppl), 45-59.
58. TATTON, W. G. & CHALMERS-REDMAN, R. M. (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47, S171-S183.
59. TATTON, W. G., CHALMERS-REDMAN, R. M., ELSTNER, M., LEESCH, W., JAGODZINSKI, F. B., STUPAK, D. P., SUGRUE, M. M. & TATTON, N. A. (2000) Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. Journal of Neural Transmission 60(Suppl), 77-100.
60. TORONYI, E., HAMAR, J., MAGYAR, K. & SZENDE, B. (2002) Antiapoptotic effect of (-)-deprenyl in rat kidney after ischemia-reperfusion. Medical Science Monitoring 8, BR65-BR68.
61. UNAL, I., GURSOY-OZDEMIR, Y., BOLAY, H., SOYLEMEZOGLU, F., SARIBAS, O. & DALKARA, T. (2001) Chronic daily administration of selegiline and EGb 761 increases brain's resistance to ischemia in mice. Brain Research 917, 174-181.
62. VENABLE, J. R. & COGGESHALL, R. (1965) A simplified lead stain for use in electron microscopy. Journal of Cell Biology 25, 407-408.
63. WADIA, J. S., CHALMERS-REDMAN, R. M., JU, W. J., CARLILE, G. W., PHILLIPS, J. L., FRASER, A. D. & TATTON, W. G. (1998) Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: Time course and modification by (-)-deprenyl. Journal of Neuroscience 18, 932-947.
64. WALDMEIER, P. C., BOULTON, A. A., COOLS, A. R., KATO, A. C. & TATTON, W. G. (2000) Neurorescuing effects of the GAPDH ligand CGP 3466B. Journal of Neural Transmission 60(Suppl), 197-214.
65. WU, E. Y., SMITH, M. T., BELLOMO, G. & DI MONTE, D. (1990) Relationships between the mitochondrial transmembrane potential, ATP concentration, and cytotoxicity in isolated rat hepatocytes. Archives of Biochemistry & Biophysics 282, 358-362.
66. YOUDIM, M., GRUNBLATT, E., LEVITES-ROYAK, Y. & MANDEL, S. (2001) Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. Advances in Neurolology 87, 115-124.
67. YOUDIM, M. B. & WEINSTOCK, M. (2002) Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mechanisms of Ageing & Development 123, 1081-1086.
68. ZHANG, J., PERRY, G., SMITH, M. A., ROBERTSON, D., OLSON, S. J., GRAHAM, D. G. & MONTINE, T. J. (1999) Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. American Journal of Pathology 154, 1423-1429.